| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 52 | 2023 | 1241 | 5.780 |
Why?
|
| Stress Disorders, Post-Traumatic | 48 | 2023 | 1506 | 4.670 |
Why?
|
| Alcoholism | 14 | 2023 | 1109 | 1.520 |
Why?
|
| Veterans | 19 | 2023 | 904 | 1.390 |
Why?
|
| Central Nervous System Stimulants | 8 | 2020 | 221 | 1.380 |
Why?
|
| Implosive Therapy | 10 | 2022 | 171 | 1.340 |
Why?
|
| Mindfulness | 3 | 2023 | 41 | 1.200 |
Why?
|
| Community Mental Health Services | 4 | 2015 | 65 | 1.120 |
Why?
|
| Substance Abuse Treatment Centers | 10 | 2015 | 71 | 1.080 |
Why?
|
| Comorbidity | 24 | 2023 | 1425 | 0.960 |
Why?
|
| Feeding and Eating Disorders | 4 | 2015 | 106 | 0.910 |
Why?
|
| Female | 70 | 2023 | 38015 | 0.700 |
Why?
|
| Humans | 84 | 2023 | 68525 | 0.630 |
Why?
|
| Adult | 57 | 2022 | 21375 | 0.630 |
Why?
|
| Treatment Outcome | 32 | 2023 | 7028 | 0.610 |
Why?
|
| Anxiety Disorders | 5 | 2020 | 426 | 0.570 |
Why?
|
| Marijuana Abuse | 6 | 2017 | 251 | 0.560 |
Why?
|
| Hot Flashes | 1 | 2013 | 8 | 0.490 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2013 | 17 | 0.480 |
Why?
|
| Menopause | 1 | 2013 | 47 | 0.480 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2013 | 22 | 0.480 |
Why?
|
| Patient Dropouts | 4 | 2018 | 98 | 0.480 |
Why?
|
| Cocaine-Related Disorders | 6 | 2016 | 504 | 0.480 |
Why?
|
| Opioid-Related Disorders | 4 | 2023 | 298 | 0.460 |
Why?
|
| Secondary Prevention | 5 | 2023 | 291 | 0.460 |
Why?
|
| Psychotherapy | 7 | 2022 | 253 | 0.460 |
Why?
|
| Social Work | 1 | 2013 | 27 | 0.440 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2020 | 782 | 0.400 |
Why?
|
| Financial Support | 1 | 2011 | 5 | 0.400 |
Why?
|
| Middle Aged | 38 | 2020 | 21119 | 0.390 |
Why?
|
| Male | 47 | 2020 | 37281 | 0.390 |
Why?
|
| Health Status | 1 | 2013 | 429 | 0.390 |
Why?
|
| Marijuana Smoking | 1 | 2012 | 108 | 0.380 |
Why?
|
| Substance Abuse Detection | 6 | 2023 | 66 | 0.380 |
Why?
|
| Cocaine | 3 | 2023 | 555 | 0.370 |
Why?
|
| Severity of Illness Index | 11 | 2020 | 1851 | 0.350 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 8 | 2021 | 151 | 0.350 |
Why?
|
| Motivation | 5 | 2015 | 561 | 0.330 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 6 | 2018 | 19 | 0.320 |
Why?
|
| Residential Treatment | 2 | 2015 | 24 | 0.320 |
Why?
|
| Patient Compliance | 4 | 2015 | 402 | 0.310 |
Why?
|
| Clinical Trials as Topic | 3 | 2018 | 848 | 0.300 |
Why?
|
| United States | 16 | 2021 | 7335 | 0.290 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 2017 | 435 | 0.290 |
Why?
|
| Adolescent | 20 | 2020 | 8903 | 0.260 |
Why?
|
| Acetylcysteine | 2 | 2020 | 296 | 0.260 |
Why?
|
| Self Report | 4 | 2023 | 370 | 0.260 |
Why?
|
| Self-Help Groups | 2 | 2016 | 38 | 0.250 |
Why?
|
| Dissociative Disorders | 2 | 2022 | 16 | 0.240 |
Why?
|
| Medical Records | 1 | 2004 | 121 | 0.230 |
Why?
|
| Naltrexone | 1 | 2004 | 195 | 0.220 |
Why?
|
| Amphetamine-Related Disorders | 3 | 2016 | 92 | 0.220 |
Why?
|
| Young Adult | 15 | 2020 | 5708 | 0.220 |
Why?
|
| Buspirone | 2 | 2015 | 36 | 0.220 |
Why?
|
| Acupuncture, Ear | 1 | 2002 | 4 | 0.220 |
Why?
|
| Mental Disorders | 5 | 2017 | 659 | 0.220 |
Why?
|
| Cannabis | 2 | 2023 | 115 | 0.220 |
Why?
|
| Psychophysiologic Disorders | 1 | 2002 | 20 | 0.220 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2017 | 77 | 0.220 |
Why?
|
| Ambulatory Care | 5 | 2012 | 339 | 0.210 |
Why?
|
| Expert Testimony | 1 | 2021 | 47 | 0.210 |
Why?
|
| Double-Blind Method | 8 | 2020 | 1737 | 0.200 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2020 | 8 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2021 | 141 | 0.190 |
Why?
|
| Single Parent | 1 | 2000 | 2 | 0.190 |
Why?
|
| Cannabinoids | 3 | 2017 | 90 | 0.190 |
Why?
|
| Child of Impaired Parents | 1 | 2000 | 18 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2017 | 467 | 0.190 |
Why?
|
| Mother-Child Relations | 1 | 2000 | 43 | 0.190 |
Why?
|
| Child Behavior | 1 | 2000 | 56 | 0.180 |
Why?
|
| Galvanic Skin Response | 1 | 2000 | 67 | 0.180 |
Why?
|
| Arousal | 1 | 2000 | 168 | 0.170 |
Why?
|
| Aged | 16 | 2020 | 14842 | 0.170 |
Why?
|
| Iraq War, 2003-2011 | 3 | 2017 | 85 | 0.170 |
Why?
|
| Veterans Health | 2 | 2017 | 61 | 0.170 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 546 | 0.170 |
Why?
|
| Military Personnel | 2 | 2018 | 220 | 0.170 |
Why?
|
| Craving | 2 | 2018 | 200 | 0.160 |
Why?
|
| Exercise Therapy | 1 | 2020 | 183 | 0.160 |
Why?
|
| Combined Modality Therapy | 6 | 2021 | 951 | 0.160 |
Why?
|
| Psychotherapy, Group | 3 | 2009 | 55 | 0.160 |
Why?
|
| Needs Assessment | 1 | 2019 | 185 | 0.160 |
Why?
|
| Depressive Disorder | 3 | 2018 | 621 | 0.160 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2017 | 22 | 0.150 |
Why?
|
| Psychological Techniques | 1 | 2017 | 17 | 0.150 |
Why?
|
| Token Economy | 2 | 2007 | 12 | 0.150 |
Why?
|
| Nutrition Surveys | 1 | 2018 | 204 | 0.150 |
Why?
|
| Prevalence | 5 | 2020 | 1609 | 0.150 |
Why?
|
| Health Personnel | 1 | 2019 | 286 | 0.140 |
Why?
|
| Vilazodone Hydrochloride | 1 | 2015 | 6 | 0.140 |
Why?
|
| Combat Disorders | 1 | 2017 | 102 | 0.140 |
Why?
|
| Sertraline | 2 | 2008 | 62 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2017 | 111 | 0.140 |
Why?
|
| Surveys and Questionnaires | 5 | 2021 | 2798 | 0.140 |
Why?
|
| Alcohol-Related Disorders | 1 | 2017 | 95 | 0.140 |
Why?
|
| Health Services Accessibility | 2 | 2019 | 581 | 0.140 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2016 | 41 | 0.140 |
Why?
|
| Risk Factors | 3 | 2015 | 5719 | 0.140 |
Why?
|
| Regression Analysis | 2 | 2017 | 737 | 0.140 |
Why?
|
| Resilience, Psychological | 1 | 2016 | 43 | 0.130 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2015 | 34 | 0.130 |
Why?
|
| Sex Factors | 6 | 2020 | 1265 | 0.130 |
Why?
|
| Goals | 1 | 2015 | 65 | 0.130 |
Why?
|
| Family Characteristics | 1 | 2015 | 44 | 0.130 |
Why?
|
| Puerperal Disorders | 1 | 1995 | 20 | 0.130 |
Why?
|
| Research Design | 3 | 2017 | 729 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 503 | 0.130 |
Why?
|
| Exercise | 1 | 2020 | 657 | 0.120 |
Why?
|
| Patient Admission | 1 | 2015 | 99 | 0.120 |
Why?
|
| Iran | 1 | 2013 | 12 | 0.120 |
Why?
|
| Linear Models | 1 | 2015 | 521 | 0.120 |
Why?
|
| Feasibility Studies | 2 | 2015 | 652 | 0.120 |
Why?
|
| Spouses | 1 | 2013 | 51 | 0.120 |
Why?
|
| Mothers | 1 | 1995 | 172 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2016 | 331 | 0.110 |
Why?
|
| Methamphetamine | 3 | 2016 | 132 | 0.110 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1993 | 14 | 0.110 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2022 | 257 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2015 | 374 | 0.100 |
Why?
|
| Referral and Consultation | 4 | 2019 | 383 | 0.100 |
Why?
|
| Depression | 2 | 2017 | 942 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 1995 | 286 | 0.100 |
Why?
|
| Rehabilitation, Vocational | 1 | 2011 | 14 | 0.100 |
Why?
|
| Risk-Taking | 2 | 2011 | 210 | 0.100 |
Why?
|
| Unemployment | 2 | 2011 | 18 | 0.100 |
Why?
|
| Health Facility Administrators | 1 | 2011 | 9 | 0.100 |
Why?
|
| Education | 1 | 2011 | 83 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 3256 | 0.100 |
Why?
|
| Obesity | 1 | 2018 | 1074 | 0.100 |
Why?
|
| Propylamines | 1 | 2010 | 22 | 0.100 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2010 | 20 | 0.100 |
Why?
|
| Factor Analysis, Statistical | 2 | 2022 | 201 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2013 | 403 | 0.100 |
Why?
|
| South Carolina | 4 | 2019 | 2750 | 0.090 |
Why?
|
| Socioeconomic Factors | 4 | 2020 | 955 | 0.090 |
Why?
|
| Quality of Life | 2 | 2021 | 1515 | 0.090 |
Why?
|
| Employment | 1 | 2011 | 154 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2018 | 714 | 0.090 |
Why?
|
| Health Education | 2 | 2009 | 279 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2015 | 702 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2011 | 392 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2013 | 2264 | 0.090 |
Why?
|
| Liver Transplantation | 1 | 1993 | 400 | 0.090 |
Why?
|
| Anti-Anxiety Agents | 1 | 2009 | 107 | 0.080 |
Why?
|
| Financing, Government | 1 | 2008 | 16 | 0.080 |
Why?
|
| Patient Selection | 1 | 1993 | 592 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2018 | 1341 | 0.080 |
Why?
|
| Time Factors | 5 | 2017 | 4655 | 0.080 |
Why?
|
| Bulimia Nervosa | 1 | 2008 | 21 | 0.080 |
Why?
|
| Telemedicine | 1 | 2017 | 699 | 0.080 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 189 | 0.080 |
Why?
|
| Risperidone | 1 | 2008 | 48 | 0.080 |
Why?
|
| Craniotomy | 1 | 2008 | 33 | 0.080 |
Why?
|
| Sexual Behavior | 1 | 2009 | 179 | 0.080 |
Why?
|
| Anorexia Nervosa | 1 | 2008 | 52 | 0.080 |
Why?
|
| Craniocerebral Trauma | 1 | 2008 | 50 | 0.080 |
Why?
|
| Decompression, Surgical | 1 | 2008 | 55 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2008 | 223 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 929 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 424 | 0.080 |
Why?
|
| Rural Population | 2 | 2019 | 397 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1085 | 0.070 |
Why?
|
| Antipsychotic Agents | 1 | 2008 | 247 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 334 | 0.070 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 498 | 0.070 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2004 | 53 | 0.060 |
Why?
|
| Triazoles | 1 | 2004 | 43 | 0.060 |
Why?
|
| Documentation | 1 | 2004 | 83 | 0.060 |
Why?
|
| Community Health Services | 1 | 2004 | 141 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2015 | 295 | 0.060 |
Why?
|
| Alcohol Drinking | 2 | 2020 | 805 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2023 | 96 | 0.050 |
Why?
|
| Recurrence | 2 | 2017 | 948 | 0.050 |
Why?
|
| Age Factors | 2 | 2020 | 1860 | 0.050 |
Why?
|
| Personality Inventory | 2 | 2009 | 196 | 0.050 |
Why?
|
| Fear | 1 | 2023 | 239 | 0.050 |
Why?
|
| Child | 3 | 2015 | 6400 | 0.050 |
Why?
|
| Oxytocin | 1 | 2023 | 124 | 0.050 |
Why?
|
| Extinction, Psychological | 1 | 2023 | 240 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2015 | 3185 | 0.050 |
Why?
|
| Syndrome | 1 | 2021 | 255 | 0.050 |
Why?
|
| Adaptation, Psychological | 2 | 2017 | 447 | 0.050 |
Why?
|
| Suicidal Ideation | 1 | 2021 | 106 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 42 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 260 | 0.040 |
Why?
|
| Family Therapy | 1 | 2000 | 82 | 0.040 |
Why?
|
| Psychometrics | 1 | 2022 | 514 | 0.040 |
Why?
|
| Suicide | 2 | 2016 | 115 | 0.040 |
Why?
|
| Opiate Substitution Treatment | 1 | 2019 | 57 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2015 | 2453 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 196 | 0.040 |
Why?
|
| Buprenorphine | 1 | 2019 | 67 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 444 | 0.040 |
Why?
|
| Emotions | 1 | 2019 | 244 | 0.040 |
Why?
|
| Counseling | 2 | 2011 | 279 | 0.040 |
Why?
|
| Health Surveys | 2 | 2010 | 488 | 0.040 |
Why?
|
| Help-Seeking Behavior | 1 | 2017 | 13 | 0.040 |
Why?
|
| New York | 1 | 2017 | 223 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 378 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2020 | 326 | 0.040 |
Why?
|
| Patient Care Management | 1 | 2017 | 40 | 0.040 |
Why?
|
| Alcoholics Anonymous | 1 | 2016 | 13 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2013 | 1039 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 791 | 0.040 |
Why?
|
| Mass Screening | 2 | 2015 | 837 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 2017 | 112 | 0.040 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2015 | 11 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2077 | 0.030 |
Why?
|
| Motivational Interviewing | 1 | 2015 | 40 | 0.030 |
Why?
|
| North Carolina | 1 | 2015 | 224 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 59 | 0.030 |
Why?
|
| Personality Disorders | 1 | 1995 | 43 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2008 | 1054 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 386 | 0.030 |
Why?
|
| Aftercare | 1 | 1995 | 114 | 0.030 |
Why?
|
| Gulf War | 1 | 2013 | 22 | 0.030 |
Why?
|
| Indians, North American | 1 | 2013 | 64 | 0.030 |
Why?
|
| Afghan Campaign 2001- | 1 | 2013 | 78 | 0.030 |
Why?
|
| Ethics, Professional | 1 | 1993 | 8 | 0.030 |
Why?
|
| Judicial Role | 1 | 1993 | 6 | 0.030 |
Why?
|
| Mentally Ill Persons | 1 | 1993 | 14 | 0.030 |
Why?
|
| Patient Preference | 1 | 2013 | 57 | 0.030 |
Why?
|
| Psychiatric Nursing | 1 | 1993 | 33 | 0.030 |
Why?
|
| HIV Infections | 2 | 2011 | 775 | 0.030 |
Why?
|
| Schizophrenia | 1 | 1993 | 206 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 186 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 218 | 0.020 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2010 | 14 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 2222 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2017 | 824 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 195 | 0.020 |
Why?
|
| Bulimia | 1 | 2010 | 72 | 0.020 |
Why?
|
| Sample Size | 1 | 2009 | 79 | 0.020 |
Why?
|
| Unsafe Sex | 1 | 2009 | 34 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2008 | 7264 | 0.020 |
Why?
|
| Pregnancy | 1 | 1995 | 2331 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 2891 | 0.020 |
Why?
|
| Inservice Training | 1 | 2008 | 68 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2008 | 65 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 3702 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 174 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2008 | 260 | 0.020 |
Why?
|
| Drug-Seeking Behavior | 1 | 2010 | 213 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2010 | 297 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 2356 | 0.020 |
Why?
|
| Demography | 1 | 2008 | 279 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 306 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 4843 | 0.020 |
Why?
|
| Anxiety | 1 | 2009 | 422 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2008 | 298 | 0.020 |
Why?
|
| Marital Status | 1 | 2003 | 65 | 0.010 |
Why?
|
| Piperazines | 1 | 2004 | 206 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2003 | 117 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1139 | 0.010 |
Why?
|